Tech Center 1600 • Art Units: 1621 1623 1672 1673 1691 1693
This examiner grants 74% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18285778 | NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS | Non-Final OA | Emory University |
| 18510836 | PHARMACEUTICAL COMBINATIONS AND USES THEREOF | Non-Final OA | NOVARTIS AG |
| 18024032 | HIGH DOSE NICOTINAMIDE ADENINE DINUCLEOTIDE (NAD) PRECURSOR REGIMENS FOR REDUCTION OF INFLAMMATION IN HUMAN PATIENTS WITH PREEXISTING INFLAMMATION | Non-Final OA | University of Washington |
| 18377236 | CHEMICALLY REVERSIBLE 2`-OH ACYLATION PROTECTS RNA FROM HYDROLYTIC AND ENZYMATIC DEGRADATION | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18569379 | COMPOUNDS AND METHODS FOR TREATING OR PREVENTING AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD), AUTOSOMAL DOMINANT POLYCYSTIC LIVER DISEASE (ADPLD) AND/OR AUTOSOMAL RECESSIVE POLYCYSTIC KIDNEY DISEASE (ARPKD) | Non-Final OA | YALE UNIVERSITY |
| 17905074 | COMPOSITIONS AND METHODS CONTAINING REDUCED NICOTINAMIDE RIBOSIDE FOR PREVENTION AND TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | Final Rejection | SOCIETE DES PRODUITS NESTLE S.A. |
| 18270009 | METHODS AND MODIFIED NUCLEOSIDES FOR TREATING CORONAVIRUS INFECTIONS | Non-Final OA | SUN YAT-SEN UNIVERSITY |
| 17636532 | DIAGNOSTICS AND METHODS FOR PROGNOSING RESPONSE TO IMMUNOTHERAPY BASED ON THE METHYLATION STATUS OF IMMUNE SYNAPSE GENE SIGNATURE | Non-Final OA | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 18279687 | Synthesis of Gamma Peptide Nucleic Acid Monomers and Oligomers, and Applications Therefor | Non-Final OA | Carnegie Mellon University |
| 18243812 | METHODS FOR TREATMENT OF VIRAL INFECTIONS | Non-Final OA | Gilead Sciences, Inc. |
| 18540608 | ADVANTAGEOUS ANTI-HCV COMBINATION THERAPY | Non-Final OA | Atea Pharmaceuticals, Inc. |
| 18598617 | METHODS OF PREPARING REDUCED NICOTINAMIDE RIBOSIDE AND DERIVATIVES THEREOF | Non-Final OA | The Queen's University of Belfast |
| 18284395 | SYNTHESIS OF TRINUCLEOTIDE AND TETRANUCLEOTIDE CAPS FOR MRNA PRODUCTION | Non-Final OA | ModernaTX, Inc. |
| 18509872 | AMINO ACID COMPOUNDS WITH UNBRANCHED LINKERS AND METHODS OF USE | Non-Final OA | Pliant Therapeutics, Inc. |
| 18290533 | MEDIUM MOLECULAR WEIGHT HEPARIN FOR USE IN THE TREATMENT OF ENDOTHELIOPATHY | Non-Final OA | GLYCOS BIOMEDICAL LTD |
| 18287143 | TREATMENT FOR VIRAL INFECTION WITH POLYENE MACROLIDE ANTIBIOTIC | Non-Final OA | PANNONPHARMA GYÓGYSZERGYÁRTÓ KFT. |
| 18551834 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | Non-Final OA | CustomArray, Inc. |
| 18257986 | BIOMASS REMOVAL BY CENTRIFUGATION | Non-Final OA | Glycom A/S |
| 18258656 | NOVEL GALACTOSIDE INHIBITOR OF GALECTINS | Non-Final OA | GALECTO BIOTECH AB |
| 18257724 | PGC-1alpha EXPRESSION PROMOTING AGENT, MUSCLE-BUILDING AGENT AND MITOCHONDRIA ACTIVATING AGENT | Final Rejection | YAMASA CORPORATION |
| 18022062 | NOVEL 5'CAP ANALOG HAVING CAP2 STRUCTURE AND PREPARATION METHOD THEREFOR | Non-Final OA | Shenzhen Rhegen Biotechnology Co., Ltd. |
| 18327429 | METHODS OF MOBILIZING MARROW INFILTRATING LYMPHOCYTES AND USES THEREOF | Non-Final OA | Crescent Biopharma, Inc. |
| 18026568 | METHODS AND COMPOSITIONS FOR TREATING VIRAL INFECTIONS WITH DOUBLE AND TRIPLE COMBINATIONS OF ANTIVIRAL AND IMMUNE MODULATING COMPOUNDS | Final Rejection | IATERION, INC. |
| 18023029 | DENDRIMER-DRUG CONJUGATE | Non-Final OA | Starpharma Pty Ltd. |
| 17906194 | COENZYME Q PRODUCTION ACCELERATOR AND METHOD FOR ACCELERATING COENZYME Q PRODUCTION | Final Rejection | Tsunemaru Tanaka |
| 17055591 | COMPOUNDS AND METHODS FOR MODULATION OF G-PROTEIN-COUPLED RECEPTORS | Non-Final OA | PRIMETIME LIFE SCIENCES, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy